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Abstract 
Cirrhosis is a disease which may develop as a consequence of various conditions. In advanced 
liver disease, blood coagulation can be seriously affected. Portal hypertension, vascular 
abnormalities and/or a dysbalance in coagulation factors may result in bleeding disorders or in 
the development of thrombosis. Fibrinogen is the main protein involved in clot formation and 
wound healing. The aim of this work was to analyse the glycosylation pattern of the isolated 
fibrinogen molecules by lectin-based protein microarray, together with the carbonylation pattern 
of the individual fibrinogen chains, possible changes in the molecular secondary and tertiary 
structure and reactivity with the insulin-like growth factor-binding protein 1 (IGFBP-1) in 
patients with cirrhosis. The results pointed to an increase in several carbohydrate moieties: 
tri/tetra-antennary structures, Gal β-1,4 GlcNAc, terminal α-2,3 Sia and α-1,3 Man, and a 
decrease in core α-1,6 Fuc and bi-antennary galactosylated N-glycans with bisecting GlcNAc. 
Fibrinogen Aα chain was the most susceptible to carbonylation, followed by the Bβ chain. 
Cirrhosis induced additional protein carbonylation, mostly on the α chain. Spectrofluorimetry 
and CD spectrometry detected reduction in the α-helix content, protein unfolding and/or 
appearance of modified amino acid residues in cirrhosis. The amount of complexes which 
fibrinogen forms with IGFBP-1, another factor involved in wound healing was significantly 
greater in patients with cirrhosis than in healthy individuals. A more detailed knowledge of 
individual molecules in coagulation process may contribute to deeper understanding of 
coagulopathies and the results of this study offer additional information on the possible 
mechanisms involved in impaired coagulation due to cirrhosis. 
Keywords: Fibrinogen; Glycosylation; Carbonylation; Protein structure; Protein interaction 
1. Introduction 
Cirrhosis is a disease which may develop as a consequence of various conditions such as viral 
infection, alcohol abuse, metabolic disorder, autoimmunity, congenital disease and may also be 
of the unknown origin [1]. Risk factors for developing cirrhosis are regular alcohol consumption, 
age over 50, male gender and metabolic syndrome [2]. In the advanced liver disease, blood 
coagulation can be seriously affected, as both pro- and anti-coagulation factors may become 
progressively reduced primarily due to the reduced synthetic capacity of the liver. Most bleeding 
complications which develop in cirrhosis are due to portal hypertension and vascular 
abnormalities [3]. A dysbalance in coagulation factors and a subsequent loss of endogenous 
anticoagulant mechanisms may account for the excessive formation of thrombus. It is not 
uncommon to diagnose hypercoagulable state at one site, developed from the local endothelial 
dysfunction, together with a systemic hypocoagulable condition [4,5]. 
Oxidative stress contributes to both initiation and progression of liver disease [6]. Fibrinogen or 
coagulation factor I, is the main protein involved in the clot formation and wound healing. It 
consists of two α, β and γ chains [7]. This protein is much more susceptible to oxidation than 
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other major plasma proteins such as albumin, transferrin or immunoglobulins [8]. Protein 
carbonylation increases in cirrhosis [9] and it effects fibrinogen structure and function [10]. 
Recent results have shown that modifications which occur on fibrinogen due to cirrhosis may 
contribute to the development of thrombotic complications [11].  
Another important post-translational modification of proteins is glycosylation. Glycosylation 
influences ligand-receptor recognition, protein-protein interaction and protein turnover [12]. The 
carbohydrate units on proteins contribute to protein stability and dynamics [12-14]. Thus, 
changes in protein saccharide moieties are expected to affect its function. It was already shown 
that structural changes of glycans on fibrinogen occur due to ageing and influence clotting time 
[15]. In general, glycosylation may change as a result of certain pathology, such as cancer or 
liver disease. Common to most liver diseases seems to be an increased fucosylation, branching 
and the quantity of the bisecting N-acetylglucosamine, GlcNAc [16]. Fibrinogen in patients in 
the advanced stage of cirrhosis is characterised by the low concentration, increased oxidation, 
hypersialyation, delayed conversion to fibrin and decreased fibrin permeability [17]. 
The aim of this work was to analyse the glycosylation pattern of fibrinogen molecules by lectin-
based protein microarray, together with the carbonylation pattern of the individual fibrinogen 
chains, possible changes in the molecular secondary and tertiary structure and the reactivity with 
IGFBP-1in patients with cirrhosis. IGFBP-1 participates in wound healing by both IGF 
dependent [18] and independent actions [19]. The first one is responsible for the IGF delivery to 
the site of injury and the second exploits interaction between the RGD domain in IGFBP-1 and 
α5β1integrin on cell surfaces initiating cell signalling. Fibrinogen was shown to associate with 
IGFBP-1 in vivo and its glyco-oxidation reduces the amount of complexes [20]. 
2. Materials and methods 
2.1 Samples 
Blood samples were collected from 20 healthy volunteers (9 males, 11 females, age 41-73 years) 
and 20 patients with advanced cirrhosis (12 males, 8 females, age 43-72 years) who were 
diagnosed and followed-up in the Clinical-Medical Center “Bežanijska kosa”. The patients (n = 
12) were hospitalised due to pain under the right rib, loss of body weight, increased temperature, 
nausea, vomiting, general weakness, hepatosplenomegaly and ascites. In 6 patients, the main 
reason for hospitalisation was variceal bleeding from esophagus and anemia (one patient had 
portal vein thrombosis). Two patients were hospitalised due to ulcer perforation and stomach 
pain. Blood was taken from all patients upon their admission to the hospital, prior to any 
treatment. The diagnosis of cirrhosis was made on the basis of clinical, biochemical and 
pathohistological parameters using standard techniques including ultrasound, endoscopy and 
microscopy. The etiology was recognised as excessive alcohol consumption (n = 17), chronic 
hepatitis C infection (n = 1) and miscellaneous causes (n = 2). All cases were classified as Child 
score C, decompensated. The concentration of albumin in patients was 26.0 (20.15-37.80) g/l, 
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total bilirubin 84.5 (40.04-209.10) μM, conjugated bilirubin 25.0 (9.84-117.76) μM and INR 1.8 
(0.99-2.15). All patients were hospitalised and subjected to the following therapy: Hepa-Merz 
amp. (3x2 units) and Hepasol (8 %). Additionally, patients who had active bleeding received 
transfusion of the concentrated erythrocytes if their haemoglobin concentration was below 75 g/l 
and heamtocrit below 0.26, and FFP in a dose of 10-15 ml/kg of body weight per day. 
Cryoprecipitate (7-10 units per day) was administrated to the patients who, besides active 
bleeding, had fibrinogen level below 2 g/l. Patients with platelet count bellow 20x109 /l received 
preparation of concentrated thrombocytes. Patients with INR above 2.5 received vitamin K (10-
40 mg per day) and FFP, while those with albumin below 26 g/l received 20 % albumin solution 
(100 ml per day). The exclusion criteria for patients were the following: the presence of 
congenital coagulation disorder, recent infection, HIV positive status and malignancy. The study 
was approved by Ethical Committees of the CMC “Bežanijska kosa” and the Institute INEP, and 
informed consent was obtained from patients for the use of their samples in this research. Blood 
samples from volunteers were obtained in the morning, after at least 12 h of fasting and the 
plasma separated within 1 h. Determination of protein concentrations and isolation of fibrinogen 
were performed on the same day. 
2.2 Determination of protein concentrations 
The concentration of total proteins was determined by the Biuret reagent (Human GmbH, 
Wiesbaden, Germany), fibrinogen by the Fowell reagent (Alfapanon, Novi Sad, Serbia) and 
IGFBP-1 by the ELISA test (Abcam, Cambridge, UK). 
2.3 Isolation of fibrinogen from plasma 
Fibrinogen was isolated from plasma according to the modified published procedure [21], using 
ethanol. After the first precipitation step, fibrinogen was dissolved in 10 mM PBS and the 
precipitation repeated once more in order to obtain highly purified fibrinogen. The purity of the 
isolated fibrinogen was assessed by the reducing SDS and native PAGE, followed by the CBB 
staining. The concentration of the isolated fibrinogen was determined using both Fowell reagent 
and the bicinchoninic acid (BCA) protein assay kit (Thermo Fisher Scientific, Waltham, USA). 
The choice of the method was made taking into consideration that fibrinogen had to be 
determined both in plasma and in the preparation of the isolated fibrinogen. An optical based 
coagulometer could not be employed, as this method is based on the coagulation process 
involving many coagulation factors present in plasma and absent in the preparation of the 
isolated fibrinogen. Thus, it was considered that chemical reaction for determination of 
fibrinogen would be more appropriate, possibly less affected by the altered milieu (plasma vs 
fibrinogen in the buffer solution).  
 
2.4 Analysis of fibrinogen glycosylation 
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Lectin-based protein microarray was used for the assessment of fibrinogen glycosylation. 
Individual fibrinogen samples (0.1 mg/ml in PBS) were spotted on the Nexterion slide E (Schott, 
Jena, Germany) using a spotter sciFLEXARRAYER S1 and piezo dipense capillary PDC 90 
(Scienion AG, Berlin,Germany) with the fixed drop volume of 480 pl, at 10 oC and 50 % 
humidity. Each sample was spotted in triplicate into 15 identical subarrays. After incubation at 4 
oC for 2h, the remaining free epoxy groups on slides were blocked with 3% bovine serum 
albumin in PBS for 1 h, the slide washed with PBST (PBS with 0.1 % TWEEN-20) and 15 
biotinylated lectins (Vector, Burlingame, USA) applied at the concentration of 25 µg/ml in PBST 
(Table 1). After incubation with lectins for 1h, the slide was washed with PBST and exposed to 
CF647-streptavidin conjugate (Biotium, Hayward, USA, 0.5 µg/ml in PBST) at room 
temperature for 15 min. The slide was thoroughly washed, dried and scanned in InnoScan®710 
laser fluorescent scanner (Innopsys, Carbonne, France) at a wavelength of 635 nm. Images were 
processed by the Mapix 5.5.0 software (Innopsys) and the results corrected for the background 
signal. Signal-to-noise ratio was above 3 in the case of all lectins. 
Table 1. The list of lectins used in the lectin-based protein microarray 
Lectin Carbohydrate specificity 
Griffonia simplicifolia lectin-II (GSL-II) Agalactosylated tetra/triantennary N-type 
Galanthus nivalis lectin (GNL) High-mannose type N-glycans, Man α1,3 Man 
Maackia amurensis lectin-I (MAL-I) Gal (β-1,4) GlcNAc 
Hippeastrum hybrid lectin (HHL) 
High-mannose type N-glycans, Man α1,3 Man, 
Man α1,6 Man 
Narcissus Pseudonarcissus Lectin (NPL) 
Polymannose structures containing (α-1,6) 
linkages 
Ricinus communis agglutinin-I (RCA-I) Gal β1,4 GlcNAc 
Lens culinaris agglutinin (LCA) 
α-D-Glc, α-D-Man in N-glycans with Fuc α1,6 
GlcNAc 
Aleuria aurantia lectin (AAL) Fuc α1,6 GlcNAc, Fuc α1,3 (Gal β1,4) GlcNAc 
Phaseolus vulgaris leukoagglutinin (PHA-L) Tri-/tetraantennary complex type N-glycans 
Concanavalin A (ConA) 
High-mannose type N-glycans, Man α1,6 (Man 
α1,3) Man 
Pholiota squarrosa lectin(PhoSL) Core α1–6-fucosylated N-glycans 
Sambucus nigra agglutinin (SNA) Terminal α2,6 Sia bound to Gal or GalNAc 
Phaseolus vulgaris erythtroagglutinin (PHA-E) 
Bi/tri-antennary complex type N-glycans with 
terminal Gal and bisecting GlcNAc 
Wheat germ agglutinin (WGA) GlcNAc β1,4 GlcNAc 
Maackia amurensis lectin-II (MAL-II) Terminal α2,3 Sia bound to Gal 1,4 GlcNAc 
 
2.5 Analysis of fibrinogen carbonylation 
In order to determine a degree of fibrinogen carbonylation and investigate which chains are 
prone to oxidation, 6 pools of the isolated fibrinogen (2 mg/ml), were analysed: 3 from each 
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study group (healthy individuals or patients with cirrhosis). Pools were made by using equal 
quantities of fibrinogen isolated from 6-7 persons. Fibrinogen carbonyl groups were derivatised 
with 2,4-DNP, [22] and the samples analysed by the reducing SDS PAGE on 10 % gels [23]. 
Proteins were transferred to the nitrocellulose membrane, stained with the Ponceau S and 
subjected to immunoblotting using rabbit anti-DNP antibody (Sigma, Steinheim, Germany), 
HRP-conjugated secondary anti-rabbit IgG antibody (AbD Serotec, Kidlington, UK) and the 
ECL reagent (Pierce Biotechnology, Rockford, USA). Proteins were visualised by 
autoradiography. Densitometric analysis was done using the Image Master TotalLab software 
(Amersham BioSciences, Buckinghamshire, UK). 
2.6 Analysis of fibrinogen by spectrofluorimetry 
Six pools of the isolated fibrinogen samples (40 nM, made as explained in the section 2.5) were 
analysed by spectrofluorimetry. Fluorescence spectra were obtained on the FluoroMax®-4 
spectrofluorimeter (HORIBA Scientifc, Japan), with the width of the excitation and emission 
slits adjusted at 5 nm. Spectra were recorded in 2 ranges: 290-400 nm (after the excitation at 280 
nm) and 310-400 nm (after the excitation at 295 nm). Spectra were corrected for the background 
signal originating from the buffer.  
2.7 Analysis of fibrinogen by CD spectroscopy 
CD measurements were performed on the Jasco J-815 spectropolarimeter (Jasco, Tokyo, Japan). 
Far-UV CD spectra of 6 pooled fibrinogen samples (made as explained in the section 2.5), at 
protein concentration of 1μM, were recorded in the range of 185-260 nm, at a scan speed of 50 
nm/min, using a cell with an optical path length of 0.1 mm and with an accumulation of three 
scans. Near-UV CD spectra of the same solutions were recorded in the range of 250-350 nm, at a 
scan speed of 50 nm/min, using a cell with an optical path length of 10 mm and with an 
accumulation of two scans. 
2.8 Analysis of the interaction between fibrinogen and IGFBP-1 
In order to detect the interaction between fibrinogen and IGFBP-1, individual fibrinogen samples 
(0.4 mg/ml) were subjected to the native PAGE on 8 % gels and immunoblotting using rabbit 
anti-IGFBP-1 (AbD Serotec) or goat anti-fibrinogen (Abcam) primary antibody. Biotinylated 
secondary anti-goat IgG antibody, coupled with the HRP-conjugated avidin (Vector) or HRP-
conjugated secondary anti-rabbit IgG antibody (AbD Serotec) and the ECL reagent (Pierce 
Biotechnology) were applied for the immunodetection. Densitometric analysis was performed 
using the Image Master Total Lab software (Amersham BioSciences). The IGFBP-1 
immunoblotting was performed first, then the membrane was stripped, fibrinogen detected and 
the results presented as the ratio of IGFBP-1 to fibrinogen signals. 
2.9. Statistical analysis 
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All data are presented as medians with the percentile rank (2.5th– 97.5th). In the case of the 
normally distributed data, the statistical difference between the groups was analysed by the 
Student’s t-test. Mann-Whitney U test was performed for the non-normally distributed data.   
3. Results and discussion 
Determination of the protein concentration revealed that total proteins in plasma were 
significantly reduced in patients with cirrhosis, the concentration of fibrinogen remained in a 
similar range as in healthy persons, whereas the concentration IGFBP-1 increased more than 
twice in patients (Table 2). 
Table 2. The concentrations of proteins in plasma samples obtained from healthy persons and the 
patients with cirrhosis (medians with the percentile rank, 2.5th – 97.5th) 
 
 
 
 
 
 
 
 
 
 
 
These results are in agreement with the already published data, as hypoproteinemia is a common 
feature in patients with cirrhosis, while fibrinogen may remain within the reference range or 
decrease in the advanced stages of cirrhosis [24-25]. Since the fibrinogen level increases in 
inflammatory states [26] and cirrhosis may be accompanied by inflammation, the final 
concentration of fibrinogen is a result of the equilibrium between two opposing processes 
(inflammation and reduced synthetic capacity of the liver). An increase in IGFBP-1 
concentration due to cirrhosis was detected in several studies [27-30]. 
Although plasma concentrations of fibrinogen in two study groups were similar, the difference 
between samples became evident during the isolation of fibrinogen. Fibrinogen from healthy 
persons was almost quantitatively precipitated by ethanol, resulting in the concentration of 3.1 
(2.13-4.78) mg/ml, when normalized to 1 ml of plasma. By using two methods to determine the 
concentration of isolated fibrinogen, a specific one (Fowell) and a general for proteins (BCA), 
we could conclude that the isolated protein was just fibrinogen. The recovery of fibrinogen was 
93 (87.2-99.0) %. The purity of the preparation was confirmed by the reducing SDS and native 
PAGE (Figure 1). On the contrary, fibrinogen from the patients with cirrhosis was rarely 
precipitated quantitatively, resulting in the concentration of 2.5 (0.80-4.44) mg/ml. The recovery 
of fibrinogen was 67 (36.4-72.1) % and the preparation contained only fibrinogen (Figure 1). 
Protein 
concentrations 
  
Healthy persons 
(n = 20) 
 
Patients with 
cirrhosis 
(n = 20) 
Total proteins 
(g/l) 
75.3 (67.42-80.67) 
53.8 (45.80-64.25) 
p = 5.344 x 10-7 
Fibrinogen 
(g/l) 
3.3 (2.45-4.79) 
3.8 (2.22-6.15) 
p = 0.119 
IGFBP-1 
(µg/l) 
15.3 (1.12-42.97) 
 
37.7 (9.21-108.27) 
p = 0.005 
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The difference in the efficiency of fibrinogen isolation between these two groups was significant 
(p = 0.001). Such difference pointed to the altered plasma milieu due to cirrhosis, which disabled 
complete precipitation of the protein by the procedure optimized for the isolation of fibrinogen 
from plasma originating from healthy persons. 
 
Figure 1. The CBB staining of the isolated fibrinogen resolved by the reducing SDS PAGE on 10 
% gel (left panel) and native PAGE on 8 % gel (right panel). Five isolated fibrinogen samples 
(representative) are shown: 2 from healthy persons (H1-2) and 3 from patients with cirrhosis 
(C1-3). 
The assessment of the glycosylation pattern of fibrinogen by the lectin-based protein microarray 
revealed that cirrhosis induced changes in fibrinogen glycosylation. As it can be seen in Table 3, 
significant differences (compared to the healthy persons) were observed with lectins PhoSL, 
MAL-I, MAL-II, GNL, PHA-L and PHA-E. The results pointed to an increase in several 
carbohydrate moieties: tri/tetra-antennary structures, Galβ-1,4GlcNAc, terminal α-2,3 Sia and α-
1,3 Man. On the other hand, the core α-1,6Fuc and bi-antennary galactosylated N-glycans with 
the bisecting GlcNAc were reduced in cirrhosis.  
An increase of Sia residues on fibrinogen due to the liver diseases was previously reported [31]. 
A similar increase of terminal Sia residues and glycan branching was detected on transferrin in 
patients with liver cancer [32]. Sia is negatively charged and fibrin clots obtained from the 
patients with cirrhosis have higher density [11]. Sia residues are the binding sites for calcium 
ions. This interaction may facilitate clot formation [33], but can also induce an increase in total 
calcium in plasma (free plus protein-bound), contributing to an overall hypercalcemia, a well-
known feature of the advanced chronic liver disease [34-35] and a risk factor for development of 
thrombosis. Increased fucosylation was detected in the patients with liver disease; in whole 
serum, on α1-acid glycoprotein or haptoglobin [36-38]. An increase in α-1,6 Fuc bound to 
GlcNAc was also detected in this study, but the change was below the statistical significance. 
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Reduction in the core Fuc on fibrinogen suggests that glycosylation of different proteins may be 
differently affected by cirrhosis. The importance of glycans on fibrinogen for its proper function 
was already documented. Deglycosylation or modified glycosylation alters its coagulation 
properties possibly leading to a complete dysfunction [39-43]. The altered glycosylation of 
fibrinogen due to ageing affects its clotting time [15].  
Table 3.The reactivity of the isolated fibrinogen obtained from healthy persons and the patients 
with cirrhosis with lectins and IGFBP-1 (medians with the percentile rank, 2.5th – 97.5th) 
Reactivity of fibrinogen 
with lectins 
(arbitrary fluorescence 
units) 
Healthy persons 
(n = 20) 
Patients with cirrhosis 
(n = 20) 
GSL-II 1.9 (1.433-2.023) 2.0 (1.80-2.09) 
p = 0.070 
GNL 1.8 (1.29-1.99) 1.9 (1.81-1.93) 
p = 0.033 
MAL-I 1.0 (0.79-1.32) 1.2 (1.03-1.26) 
p = 0.016 
HHL 1.2 (0.95-1.35) 1.2 (1.10-1.27) 
p = 0.732 
NPL 1.9 (1.47-2.22) 2.0 (1.87-2.12) 
p = 0.569 
RCA-I 3.2 (3.12-3.28) 3.2 (2.90-3.23) 
p = 0.094 
LCA 2.3 (2.11-2.60) 2.3 (2.18-2.41) 
p = 0.972 
AAL 2.2 (2.00-2.51) 2.3 (2.12-2.44) 
p = 0.539 
PHA-L 1.5 (1.29-1.77) 1.7 (1.61-1.79) 
p = 0.004 
ConA 3.1 (3.04-3.18) 3.1 (2.89-3.17) 
p = 0.452 
PhoSL 2.4 (2.28-2.45) 2.3 (2.19-2.38) 
p = 0.010 
SNA 3.1 (3.02-3.11) 3.0 (2.89-3.09) 
p = 0.073 
PHA-E 2.5 (2.40-2.71) 2.5 (2.26-2.59) 
p = 0.046 
WGA 2.3 (2.08-2.58) 2.3 (1.99-2.38) 
p = 0.269 
MAL-II 1.7 (1.52-2.02) 2.0 (1.63-2.11) 
p = 0.007 
Reactivity of fibrinogen 
with IGFBP-1 (ratio of 
densitometric signals) 
    
IGFBP-1/fibrinogen 
0.1 (0.04-0.19) 0.2 (0.03-0.28) 
p = 0.044 
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The assessment of the carbonylation pattern of fibrinogen revealed that the Aα chain was the 
most susceptible to carbonylation followed by the Bβ chain (Figure 2). There was no DNP 
immunoreactive signal detected on the γ chain. The same type of results was obtained with 
fibrinogen originating from the either study group. Xu and co-workers [44] reported that α chain 
of fibrinogen is the most susceptible chain to interaction with the reactive oxygen species in 
vitro, followed by the β chain. Our finding that α and β chains of fibrinogen are primarily (and 
perhaps exclusively) oxidatively modified in vivo in patients with cirrhosis may contribute to the 
better understanding of changes which accompany coagulation process, since α and β chains 
contain sites for the cleavage by thrombin. Upon the release of fibrinopeptides A and B by 
thrombin, polymerisation sites are liberated to participate in the initial end-to-middle association 
of fibrin monomers and the formation of double-stranded fibrils, as well as for the lateral 
associations to create multi-stranded fibrils. Additionally, the αC domains are important as they 
can mutually interact favouring the lateral growth of fibrin fibrils [7,10,45-46]. The data obtained 
both in vivo and in vitro have shown that fibrinogen carbonylation affects its function [10,44,47-
49]. When results on fibrinogen carbonylation were compared between healthy persons and the 
patients with cirrhosis in this study (densitometric signals normalized to the protein 
concentrations), it was found that cirrhosis induced additional protein carbonylation, mostly on 
the α chain. The intensity of densitometric signals in the patients was 38.5 (25.40-51.58) and in 
healthy persons 17.3 (16.81-34.60), which is also in agreement with the published data [11]. 
 
Figure 2. The Ponceau S staining (left panel) and immunoblot with anti-DNP antibody (right 
panel) of the fibrinogen chains derivatised with DNP and resolved by the reducing SDS PAGE 
on a 10 % gel. Six pools of the isolated fibrinogen were analysed: 3 from each study group 
(healthy persons, H1-3 and the patients with cirrhosis, C1-3).  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
11 
 
In order to investigate possible changes of the fibrinogen structure due to cirrhosis, several 
experiments were performed (Figure 3). Far-UV CD spectra of fibrinogen displayed typical 
signal for the α-helix (negative bands at 209 and 222 nm), as it is its dominant secondary 
structure. Reduction in the α-helix content in fibrinogen originating from the patients with 
cirrhosis compared to the healthy persons was observed (Figure 3A). Becatti and co-workers [48] 
reported a reduction in the fibrinogen α-helix structure due to oxidation in the patients with 
myocardial infarction, which resulted in the formation of denser clots. Judging from the data 
from our study and some other published results [11], it is possible that similar structure-function 
relationship can be attributed to fibrinogen in patients with cirrhosis. Near-UV CD spectra 
showed slight differences between two groups (Figure 3B), suggesting the possible change in the 
protein tertiary structure. Spectrofluorimetric analysis (Figure 3C and 3D), revealed a reduction 
in the intrinsic fluorescence of fibrinogen from the patients, confirming that its tryptophan 
residues resided in the altered surrounding. This feature can be a consequence of either protein 
unfolding or the appearance of modified amino acid residues. Based on these results, it is 
plausible to suspect that structural changes of fibrinogen can be attributed to the changes in the 
glycosylation and/or oxidation, but this was not definitely confirmed. 
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Figure 3. The analysis of the secondary and tertiary structure of fibrinogen: far-UV CD spectra 
(A), near-UV CD spectra (B), fluorescence spectra after excitation at 280 nm (C), or 295 nm (D). 
The results for 4 pools of the isolated fibrinogen are shown: one from healthy persons (Control) 
and 3 from the patients with cirrhosis (Cirrhosis 1-3).   
Investigation of fibrinogen reactivity with the IGFBP-1 demonstrated that the amount of IGFBP-
1/fibrinogen complexes was significantly greater in the patients with cirrhosis than in healthy 
individuals (Table 3 and Figure 4). Taking into account that the concentration of IGFBP-1 was 
much higher in patients (Table 2), the finding is not unexpected. However, the increase in the 
IGFBP-1 level in patients is greater than the increase in the amount of complexes (2.5 times 
compared to 1.5 times), suggesting that other factors besides the IGFBP-1 concentration 
influenced the formation of complexes. The reduced affinity of fibrinogen for IGFBP-1, due to 
its structural modification, may be one such factor.  
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Figure 4. The immunoblot analysis of the fibrinogen/IGFBP-1 complexes subjected to the native 
PAGE on a 8 % gel with anti-IGFBP-1 (left panel) or anti-fibrinogen antibody (right panel). 
Results for 10 individual (representative) samples of the isolated fibrinogen are shown: 5 from 
each study group (healthy persons, H1-5 and the patients with cirrhosis, C1-5). 
As mentioned in the Introduction, IGFBP-1 has beneficial effects on the injured tissue either by 
delivering IGF-I [50] or by directly interacting with cells, affecting their mobility [51], secretion 
of other growth factors [52] or contributing to the wound healing [19,53]. In cirrhosis, however, 
the increased IGFBP-1 concentration at the site of injury is, perhaps, not beneficial as its action 
may contribute to thrombosis. The similar hypothesis was proposed by Ramos-Mozo and co-
workers [18] who discovered the increased IGFBP-1 concentration in patients with the 
abdominal aortic aneurysm as a risk factor. 
Conclusions 
The results of the study presented in this article pointed to significant changes in fibrinogen 
glycosylation, carbonylation, secondary and tertiary structure, as well as its reactivity with 
IGFBP-1 in the patients with cirrhosis, complementing results of other researchers on the 
coagulation anomalies due to cirrhosis [11,54]. A more detailed knowledge on the events which 
affect individual molecules in coagulation process may contribute to a deeper understanding of 
coagulopathies and, possibly, creation of better therapeutic approaches.  
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Highlights 
 Multiantennary glycans, GlcNAc, Sia and Man increase on fibrinogen in cirrhosis 
 Cirrhosis induces additional protein carbonylation, mostly on α chain 
 Reduction in α-helix content in fibrinogen occurs in cirrhosis 
 Fibrinogen forms more complexes with IGFBP-1 in cirrhosis  
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